Ticker Details
Intellia Therapeutics, Inc. Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
IPO Date:	May 6, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.46B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.10 | 3.21%
Avg Daily Range (30 D):	$0.59 | 4.53%
Avg Daily Range (90 D):	$0.51 | 3.88%

Institutional Daily Volume
Avg Daily Volume:	1.3M
Avg Daily Volume (30 D):	4.78M
Avg Daily Volume (90 D):	5.69M

Trade Size
Avg Trade Size (Sh.):	79
Avg Trade Size (Sh.) (30 D):	102
Avg Trade Size (Sh.) (90 D):	106

Institutional Trades
Total Institutional Trades:	4,876
Avg Institutional Trade:	$2.94M
Avg Institutional Trade (30 D):	$3.11M
Avg Institutional Trade (90 D):	$2.62M
Avg Institutional Trade Volume:	.09M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.82M
Avg Closing Trade (30 D):	$4.47M
Avg Closing Trade (90 D):	$4.62M
Avg Closing Volume:	161.76K

News

Feb 7, 2026 @ 2:05 PM This Cathie Wood Stock Is Already Up 41% This Year... Source: Prosper Junior Bakiny

Jan 22, 2026 @ 9:56 AM Genome Editing Market Forecast to Reach $23.6 Bill... Source: Researchandmarkets.Com

Nov 4, 2025 @ 8:35 AM Gene Editing Market Size to Surpass USD 42.13 Bill... Source: Nova One Advisor

Nov 2, 2025 @ 2:25 PM Meet the Beaten-Down Biotech Stock Cathie Wood Lov... Source: Prosper Junior Bakiny

Oct 2, 2025 @ 5:00 PM CRISPR Therapies Clinical Trial Pipeline Shows Pot... Source: Delveinsight

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$-.92	$-.98
Diluted EPS		$-.92	$-.98
Revenue		$13.78M	$14.25M
Gross Profit
Net Income / Loss		$-101.32M	$-101.26M
Operating Income / Loss		$-111.48M	$-110M
Cost of Revenue
Net Cash Flow		$37.22M	$-32.66M
PE Ratio